↑ 疾患リストへ ← 戻る

 5. 進行性核上性麻痺 [臨床試験数:55,薬物数:78(DrugBank:31),標的遺伝子数:59,標的パスウェイ数:86] 

Searched query = "Progressive supranuclear palsy"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04008355October 11, 20192 September 2019A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSPA Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 on Cerebrospinal Fluid Biomarkers in 36 Patients With Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: AZP2006 oral solution;Drug: Placebo oral solutionAlzProtect SASNot recruiting40 Years80 YearsAll36Phase 2France
2NCT03926702June 18, 201922 July 2019Tau Imaging With JNJ067Tau Imaging With JNJ067Alzheimer Disease;Mild Cognitive Impairment;Progressive Supranuclear PalsyDrug: RadiopharmaceuticalsUniversity of California, BerkeleyUniversity of California, San FranciscoRecruiting50 YearsN/AAll18Early Phase 1United States
3JPRN-UMIN0000369522019/06/0416 July 2019A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients.A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. - A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients.Patients who are suspected Parkinson's disease or related disorders, including dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, frontotemporal lobe degeneration, vascular parkinsonism, drug-induced parkinsonism, normal pressure hydrocephalus, and others.18F-FDOPA, 11C-Raclopride PETNagoya City Rehabilitation AgencyRecruiting20years-oldNot applicableMale and Female150Not applicableJapan
4NCT04014387June 2, 201929 July 2019Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)TreatmentDrug: Suvorexant;Drug: Zolpidem;Drug: Placebo oral capsuleUniversity of California, San FranciscoUS Department of Veterans AffairsRecruiting18 YearsN/AAll60Phase 4United States
5JPRN-UMIN0000365222019/04/1523 April 2019Investigator-initiated clinical trial for progressive supranuclear palsy using an anti-cholinergic drugInvestigator-initiated clinical trial for progressive supranuclear palsy using an anti-cholinergic drug - Clinical trial for PSP using anticholinergic drugProgressive supranuclear palsyTrihexyphenidyl hydrochloride max.3mg for 3 months
Placebo max. 3mg for 3 months
1) Department of Neurology, Gifu University Graduate School of Medicine, 2) National Hospital Organization, Higashi Nagoya HospitalRecruiting40years-oldNot applicableMale and Female32Not selectedJapan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6JPRN-jRCTs05118021429/03/201910 September 2019The usefulness of flutemetamol for diagnostic imaging of neurogenerative diseaseThe usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease - The usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative diseaseAlzheimer's disease,Dementia with Lewy Bodies,Parkinson's syndrome,Frontotemporal lober degeneration
Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's syndrome, Frontotemporal lober degeneration, Parkinson's disease, Mild cognitive impairment, Non-Alzheimer's disease, Progressive aphasia, Neurodegenerative disease, Cerebral corticobasal degeneration, Progressive supranuclear palsy
Amyloid PET: Given the flutemetamol (3mL) intravenously
FDG-PET:Given the FDG scanR (3mL) intravenously
Yoshiaki ItohRecruitingAges 20 and overN/ABoth100N/Anone
7JPRN-UMIN0000348342019/01/012 April 2019Detection of falling risk of progressive supranuclear palsy with inertial sensorprogressive supranuclear palsyMeasurement of muscle strength, balance test, gait analysisKawasaki University of Medical WelfareNot RecruitingNot applicableNot applicableMale and Female20Not selectedJapan,Europe
8NCT03413319April 17, 201818 December 2018Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104Progressive Supranuclear Palsy (PSP)Drug: ABBV-8E12AbbVieNot recruiting18 YearsN/AAll3Phase 1United States
9NCT03446807April 201811 June 2018Safety and Efficacy of Droxidopa for Fatigue in Patients With ParkinsonismSafety and Efficacy of Droxidopa for Fatigue in Patients With ParkinsonismParkinson Disease;Multiple System Atrophy;Progressive Supranuclear PalsyDrug: Droxidopa;Drug: Placebo Oral TabletLoma Linda UniversityH. Lundbeck A/SNot recruiting50 YearsN/AAll32Phase 2United States
10NCT03545789March 12, 20181 April 2019Phase 1 Test-retest Evaluation of [18F]MNI-958 PETPhase 1 Test-retest Evaluation of [18F]MNI-958 PET as an Imaging Marker for Tau Protein in the Brain of Patients With Alzheimer's Disease and Probable PSP as Compared to Healthy VolunteersHealthy Volunteers;Alzheimer Disease;Progressive Supranuclear PalsyDrug: [18F]MNI-958InvicroRecruiting18 Years55 YearsAll14Phase 1United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT03391765January 24, 201826 August 2019An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)Progressive Supranuclear Palsy (PSP)Drug: ABBV-8E12AbbVieNot recruiting40 YearsN/AAll142Phase 2United States;Australia;Canada;France;Italy;Japan
12NCT03625128January 2, 201828 October 201918F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal ControlsPhase 0 Evaluation of Clinical and Neuroimage (18F-PM-PBB3 PET) Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal ControlsAlzheimer's Disease;Cortical Basal Syndrome;Frontotemporal Dementia;Progressive Supranuclear Palsy;Vascular Cognitive ImpairmentDrug: F-18Chang Gung Memorial HospitalNot recruiting20 Years90 YearsAll36Early Phase 1Taiwan
13NCT03545126August 21, 20177 October 2019Human CNS Tau Kinetics in TauopathiesHuman CNS Tau Kinetics in TauopathiesProgressive Supranuclear Palsy (PSP);Corticobasal Degeneration (CBD);Frontotemporal Dementia (FTD MAPT Mutation)Other: 13C6 LeucineWashington University School of MedicineAssociation of Frontotemporal Degeneration;Tau ConsortiumRecruiting18 YearsN/AAll32N/AUnited States
14NCT03174938May 15, 201711 June 2018The Swedish BioFINDER 2 StudyThe Swedish BioFINDER 2 StudyDementia;Alzheimer Disease;Parkinson Disease;Lewy Body Disease;Parkinson-Dementia Syndrome;Frontotemporal Degeneration;Semantic Dementia;Progressive Nonfluent Aphasia;Progressive Supranuclear Palsy;Corticobasal Degeneration;Multiple System Atrophy;Mild Cognitive ImpairmentDiagnostic Test: Flutemetamol F18 Injection;Diagnostic Test: [18F]-RO6958948;Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau;Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and PtauSkane University HospitalLund UniversityRecruiting20 Years100 YearsAll1505N/ASweden
15NCT03068468April 24, 201730 September 2019Study of BIIB092 in Participants With Progressive Supranuclear PalsyA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear PalsySupranuclear Palsy, ProgressiveDrug: BIIB092;Drug: PlaceboBiogenNot recruiting41 Years86 YearsAll490Phase 2United States;Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16EUCTR2017-000094-36-SE31/03/201722 May 2017The BioFINDER 2 study - improved diagnostics and increased understanding of the underlying mechanisms of cognitive disordersThe BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disordersNeurodegenerative disorders with Tau-pathology; including, but not limited to, Alzheimers disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration and mild cognitive impairment.
MedDRA version: 19.1 Level: PT Classification code 10053643 Term: Neurodegenerative disorder System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1 Level: PT Classification code 10012267 Term: Dementia System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1 Level: PT Classification code 10067889 Term: Dementia with Lewy bodies System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1 Level: HLGT Classification code 10028037 Term: Movement disorders (incl parkinsonism) System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1 Level: PT Classification code 10012271 Term: Dementia Alzheimer's type System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1 Level: HLT Classification code 10001897 Term: Alzheimer's disease (incl subtypes) System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1 Level: LLT Classification code 10009846 Term: Cognitive impairment System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1 Level: LLT Classification code 10048598 Term: Cognitive disorders System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1 Level: LLT Classification code 10012285 Term: Dementia due to Pick's disease System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1 Level: PT Classification code 10036813 Term: Progressive supranuclear palsy System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1 Level: PT Classification code 10074616 Term: Prodromal Alzheimer's;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
Product Name: 18F-RO6958948
Pharmaceutical Form: Injection
Trade Name: Vizamyl (flutemetamol(F-18))
Product Name: Vizamyl
Pharmaceutical Form: Injection
Skåne University HospitalAuthorisedFemale: yes
Male: yes
Phase 2Sweden
17NCT02985879December 12, 20164 February 2019A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP).A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear PalsyProgressive Supranuclear Palsy (PSP)Drug: placebo;Drug: ABBV-8E12AbbVieNot recruiting40 YearsN/AAll378Phase 2United States;Australia;Canada;France;Germany;Italy;Japan;Spain
18NCT03058965November 29, 20161 April 2019Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the BrainPhase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Probable Alzheimer's Disease or Progressive Supranuclear Palsy Compared With Healthy VolunteersAlzheimer Disease;Healthy Volunteers;Progressive Supranuclear PalsyDrug: [18F]MNI-958;Drug: [18F]Florbetapir;Drug: DaTscanMolecular NeuroImagingNot recruiting50 Years90 YearsAll12Early Phase 1United States
19NCT03080051August 201616 December 2017Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the BrainPhase 0 Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Progressive Supranuclear Palsy or Alzheimer's Disease Compared to Healthy VolunteersProgressive Supranuclear Palsy;Alzheimer Disease;Healthy VolunteersDrug: [18F]MNI-952;Drug: [18F]FlorbetapirMolecular NeuroImagingNot recruiting18 Years90 YearsAll6Early Phase 1United States
20NCT02839642July 26, 201616 December 2017Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear PalsyRIVA-PSP: Efficacy of Rivastigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy: A Randomised Double Blind Placebo-controlled Clinical TrialProgressive Supranuclear Palsy (PSP)Drug: Rivastigmine;Drug: PlaceboAssistance Publique Hopitaux De MarseilleRecruiting41 Years80 YearsAll106Phase 3France
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21NCT02994719March 1, 201618 December 2018Gait Analysis in Neurological DiseaseGait Pattern Analysis in Neurological DiseaseParkinson's Disease;Parkinsonian Disorders;Atypical Parkinson Disease;Progressive Supranuclear Palsy;Multiple System Atrophy;Corticobasal Degeneration;Gait, FrontalDrug: Anti-Parkinson medication;Device: Deep Brain StimulationBeth Israel Deaconess Medical CenterRecruiting18 Years85 YearsAll110N/AUnited States
22NCT02658916February 22, 201618 March 2019Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered BIIB092 in Patients With Progressive Supranuclear Palsy Who Participated in Study CN002003Supranuclear Palsy, ProgressiveDrug: BIIB092BiogenNot recruiting41 Years86 YearsAll48Phase 1United States
23NCT02605785November 20151 April 2019A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear PalsyA Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: F-18 AV 1451Mayo ClinicRecruiting40 YearsN/AAll134N/AUnited States
24NCT02460094October 2, 201510 September 2018Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear PalsyA Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: BIIB092;Drug: PlaceboBiogenNot recruiting41 Years86 YearsAll48Phase 1United States
25NCT02494024July 201516 December 2017Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear PalsyA Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: Single dose C2N-8E12;Drug: Single dose placeboC2N DiagnosticsNot recruiting50 Years85 YearsAll32Phase 1United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26NCT02460731May 201521 January 2019Young Plasma Transfusions for Progressive Supranuclear PalsyA 6 Month, Open-Label, Pilot Futility Clinical Trial of Monthly Young Healthy Male Donor Plasma Transfusions for Progressive Supranuclear PalsyProgressive Supranuclear PalsyBiological: Fresh Frozen PlasmaUniversity of California, San FranciscoNot recruiting50 Years85 YearsAll6Phase 1United States
27NCT02531360May 20159 January 2017Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With TauopathiesPhase 0 Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Alzheimer's Disease and Other TauopathiesAlzheimer's Disease (AD);Progressive Supranuclear Palsy (PSP);Cortical Basal Syndrome (CBS);Frontal Temporal Dementia (FTD)Drug: [18F]MNI-815 (MNI-815)Molecular NeuroImagingPiramal Imaging SANot recruiting50 Years90 YearsBoth7Phase 0United States
28NCT02422485April 201511 June 2018A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear PalsyA 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: SalsalateAdam BoxerNot recruiting50 Years85 YearsAll10Phase 1United States
29EUCTR2013-003740-23-ES04/02/201521 May 2018Evaluation of masitinib in the treatment of Progressive Supranuclear PalsyA prospective, multicentre, randomised, double-blind, placebo-controlled, parallel groups, phase 2b/3 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Progressive Supranuclear Palsy (PSP)Progressive Supranuclear Palsy
MedDRA version: 14.1 Level: PT Classification code 10036813 Term: Progressive supranuclear palsy System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: masitinib 100mg
Product Code: AB1010
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Masitinib mesylate
CAS Number: 790-299-79-5
Current Sponsor code: AB1010
Other descriptive name: MASITINIB MESYLATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Product Name: masitinib 200mg
Product Code: AB1010
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Masitinib mesylate
CAS Number: 790-299-79-5
Current Sponsor code: AB1010
Other descriptive name: MASITINIB MESYLATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
AB ScienceNot RecruitingFemale: yes
Male: yes
90Phase 3Spain
30EUCTR2014-000422-38-SE19/09/20147 October 2014A study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of the protein tauAn open-label study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of tauNeurodegenerative disorders with Tau-pathology; including Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration and important differential diagnostic conditions.
MedDRA version: 17.0 Level: HLT Classification code 10001897 Term: Alzheimer's disease (incl subtypes) System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 17.0 Level: PT Classification code 10053643 Term: Neurodegenerative disorder System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 17.0 Level: LLT Classification code 10009846 Term: Cognitive impairment System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 17.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 17.0 Level: LLT Classification code 10012285 Term: Dementia due to Pick's disease System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 17.0 Level: PT Classification code 10012267 Term: Dementia System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 17.0 Level: PT Classification code 10067889 Term: Dementia with Lewy bodies System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 17.0 Level: PT Classification code 10036813 Term: Progressive supranuclear palsy System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
Product Name: 18F-AV-1451
Pharmaceutical Form: Injection
Skåne University Hospital, Region SkåneAuthorisedFemale: yes
Male: yes
Sweden
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
31NCT02167594July 201412 September 2016Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers18F-AV-1451 Injection for Brain Imaging of Tau in Subjects With Progressive Supranuclear Palsy (PSP), Subjects With Corticobasal Degeneration (CBD) and Healthy VolunteersProgressive Supranuclear Palsy;Corticobasal DegenerationDrug: 18F-AV-1451;Drug: florbetapir F18Avid RadiopharmaceuticalsNot recruiting50 Years85 YearsBoth29Phase 1United States
32NCT02133846May 201411 June 2018Safety Study of TPI-287 to Treat CBS and PSPA Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear PalsyPrimary Four Repeat Tauopathies (4RT);Corticobasal Syndrome (CBS);Progressive Supranuclear Palsy (PSP);Corticobasal Degeneration (CBD)Drug: TPI 287 2 mg/m2;Drug: TPI-287 20 mg/m2;Drug: Placebo;Drug: TPI-287 6.3 mg/m2University of California, San FranciscoCBD Solutions;Tau ConsortiumNot recruiting50 Years85 YearsAll44Phase 1United States
33EUCTR2012-005539-10-DE29/04/20142 October 2017Clinical study to investigate the efficacy and safety of two dose levels of NT 201 versus placebo in treating chronic troublesome sialorrhea in various neurological conditions.Prospective, randomized, double-blind, placebo-controlled, parallel-group multicenter study, with an extension period of dose-blinded active treatment, to investigate the efficacy and safety of two dose levels of NT 201 in treating chronic troublesome sialorrhea in various neurological conditions - SIAXI – Sialorrhea in Adults Xeomin InvestigationChronic troublesome sialorrhea resulting from neurological conditions in adults with Parkinson's disease or atypical parkinsonism (multiple system atrophy, corticobasal degeneration or progressive supranuclear palsy), or after stroke or traumatic brain injury.
MedDRA version: 18.1 Level: PT Classification code 10039424 Term: Salivary hypersecretion System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Xeomin
Pharmaceutical Form: Powder for solution for injection
INN or Proposed INN: NT 101
CAS Number: 93384-43-1
Current Sponsor code: NT 101
Other descriptive name: BOTULINUM TOXIN TYPE A
Concentration unit: U unit(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Powder for solution for injection
Route of administration of the placebo: Intraglandular use
Trade Name: Xeomin
Pharmaceutical Form: Powder for solution for injection
INN or Proposed INN: NT 101
CAS Number: 93384-43-1
Current Sponsor code: NT 101
Other descriptive name: BOTULINUM TOXIN TYPE A
Concentration unit: U unit(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Powder for solution for injection
Route of administration of the placebo: Intraglandular use
Merz Pharmaceuticals GmbHNot RecruitingFemale: yes
Male: yes
180Phase 3United States;Poland;Germany
34NCT02103894February 20149 January 2017Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy SubjectsEvaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy SubjectsAlzheimer's Disease (AD);Parkinson's Disease (PD);Chronic Traumatic Encephalopathy (CTE);Progressive Supranuclear Palsy (PSP);Frontal Temporal Dementia (FTD);Pick's Disease;TauopathiesDrug: [18F]T807 ([18F]MNI-777)Molecular NeuroImagingInstitute for Neurodegenerative DisordersNot recruiting18 Years85 YearsBoth16Phase 1United States
35NCT02214862March 201315 February 20162-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified ParkinsonismPilot, Exploratory Study With [F18]-FDDNP-PET for in Vivo Diagnose of Tauopathy in Unclassified ParkinsonismProgressive Supranuclear Palsy;Multi-System Atrophy;ParkinsonismDrug: [F18]-FDDNPFundacion Clinic per a la Recerca BiomédicaNot recruiting40 YearsN/ABoth40Phase 0Spain
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
36NCT01824121December 201219 February 2015Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of ParkinsonismAutologous Mesenchymal Stem Cell Therapy in Progressive Supranuclear Palsy: a Randomized, Double-blind, Controlled Clinical TrialProgressive Supranuclear PalsyBiological: stem cell therapyFondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoRecruiting40 YearsN/ABoth25Phase 1/Phase 2Italy
37JPRN-UMIN0000089592012/11/012 April 2019Trial of molecular hydrogen water in Multiple system atrophy and Progressive supranuclear palsyMultiple system atrophy(MSA) Progressive supranuclear palsy (PSP)hydrogen water
pseudo-water (nitrogen filling water)
Juntendo University School of Medicine, Department of NeurologyNot Recruiting20years-old80years-oldMale and Female40Phase 1Japan
38EUCTR2010-019159-23-GB22/12/201019 March 2012A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy.A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy.Progressive Supranuclear Palsy
MedDRA version: 14.0 Level: PT Classification code 10036813 Term: Progressive supranuclear palsy System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Davunetide
Product Code: AL-108
Pharmaceutical Form: Nasal spray
INN or Proposed INN: Davunetide
CAS Number: 211439-12-2
Current Sponsor code: AL-108
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 75-
Pharmaceutical form of the placebo: Nasal spray
Route of administration of the placebo: Intranasal use (Noncurrent)
Allon Therapeutics IncAuthorisedFemale: yes
Male: yes
300Phase 2/3Germany;United Kingdom;Canada;France;United States;Australia
39EUCTR2010-019159-23-DE08/11/201022 April 2013A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy.A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy.Progressive Supranuclear Palsy
MedDRA version: 14.1 Level: PT Classification code 10036813 Term: Progressive supranuclear palsy System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Davunetide
Product Code: AL-108
Pharmaceutical Form: Nasal spray
INN or Proposed INN: Davunetide
CAS Number: 211439-12-2
Current Sponsor code: AL-108
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 75-
Pharmaceutical form of the placebo: Nasal spray
Route of administration of the placebo: Intranasal use (Noncurrent)
Allon Therapeutics IncNot RecruitingFemale: yes
Male: yes
300Phase 2/3France;United States;Canada;Australia;Germany;United Kingdom
40NCT01110720October 201019 February 2015Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear PalsyA Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: Davunetide;Drug: PlaceboAllon TherapeuticsNot recruiting41 Years85 YearsBoth313Phase 2/Phase 3United States;Australia;Canada;France;Germany;United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
41NCT01537549September 14, 201016 December 2017Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear PalsyAn Open-label Trial of Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy (PSP): Effect Upon Oxidative Damage and Mitochondrial BiomarkersProgressive Supranuclear PalsyDrug: alpha-lipoic acid and L-acetyl carnitineWeill Medical College of Cornell UniversityNot recruiting40 Years75 YearsAll11Phase 1/Phase 2United States
42EUCTR2008-007520-26-DE24/06/201010 February 2014A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerability and Safety of Rasagiline in Subjects with Progressive Supranuclear Palsy (Phase III)A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerability and Safety of Rasagiline in Subjects with Progressive Supranuclear Palsy (Phase III)Progressive Supranuclear Palsy
MedDRA version: 12.0 Level: PT Classification code 10036813 Term: Progressive supranuclear palsy
Trade Name: Azilect
Pharmaceutical Form: Tablet
INN or Proposed INN: Rasagilin
CAS Number: 161735-79-1
Other descriptive name: RASAGILINE MESILATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1 mg-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Klinikum der Universität MünchenNot RecruitingFemale: yes
Male: yes
Phase 3Germany
43NCT01056965January 201015 April 2019Davunetide (AL-108) in Predicted Tauopathies - Pilot StudyA 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted TauopathiesPredicted Tauopathies, Including;Progressive Supranuclear Palsy;Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17;Corticobasal Degeneration Syndrome;Progressive Nonfluent AphasiaDrug: davunetide (AL-108, NAP);Drug: Placebo nasal sprayUniversity of California, San FranciscoNot recruiting40 Years85 YearsAll12Phase 1United States
44NCT01049399December 200919 February 2015Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear PalsyA Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112, a GSK-3 Inhibitor, Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: tideglusib;Drug: placeboNoscira SAi3 ResearchNot recruiting40 Years85 YearsBoth146N/AUnited States;Germany;Spain;United Kingdom
45EUCTR2009-013097-40-GB30/10/200919 March 2012A double-blind, placebo-controlled, randomized, parallel-group study evaluating the safety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3 inhibitor, versus placebo in the treatment of patients with mild to moderate Progressive Supranuclear Palsy. - TAUROSA double-blind, placebo-controlled, randomized, parallel-group study evaluating the safety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3 inhibitor, versus placebo in the treatment of patients with mild to moderate Progressive Supranuclear Palsy. - TAUROSMild to Moderate Progressive Supranuclear Palsy
MedDRA version: 12.0 Level: LLT Classification code 10036813 Term: Progressive supranuclear palsy
MedDRA version: 12.0 Level: PT Classification code 10036813 Term: Progressive supranuclear palsy
Product Name: NP031112
Product Code: NP031112 600mg
Pharmaceutical Form: Powder for oral suspension
CAS Number: 865854-05-3
Current Sponsor code: NP031112
Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 600-
Pharmaceutical form of the placebo: Powder for oral suspension
Route of administration of the placebo: Oral use
Product Name: NP031112
Product Code: NP031112 800mg
Pharmaceutical Form: Powder for oral suspension
CAS Number: 865854-05-3
Current Sponsor code: NP031112
Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 800-
Pharmaceutical form of the placebo: Powder for oral suspension
Route of administration of the placebo: Oral use
Noscira S.A.AuthorisedFemale: yes
Male: yes
140Germany;United Kingdom;Spain
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
46NCT00703677September 200819 October 2017A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal DegenerationA Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal DegenerationProgressive Supranuclear Palsy;Corticobasal DegenerationDrug: LithiumWestatNational Institute of Neurological Disorders and Stroke (NINDS)Not recruiting40 Years80 YearsAll17Phase 1/Phase 2United States;United Kingdom
47EUCTR2006-006166-42-DE17/07/200729 May 2012Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese - offene, prospektive Phase II-Studie -Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese - offene, prospektive Phase II-Studie -Progressive supranuclear palsy (PSP) is a neurodegenerative disorder with hardly any therapeutical option to ameliorate the course of the disease. Results of first trials with physostigmine and donepezil did not point out a definite benefit. In contrast, first clinical observations concerning an effect with rivastigmine in PSP with dementia were promising. This may be due to the fact, that rivastigmine excerts a double action inhibiting both the acetylcholin- and the buturylcholinesterase.Trade Name: Exelon 1,5 mg Hartkapseln
INN or Proposed INN: RIVASTIGMINE
CAS Number: 123441032
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1,5-
Trade Name: Exelon 3,0 mg Hartkapseln
INN or Proposed INN: RIVASTIGMINE
CAS Number: 123441032
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 3,0-
Trade Name: Exelon 6,0 mg Hartkapseln
INN or Proposed INN: RIVASTIGMINE
CAS Number: 123441032
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 6-
University of TuebingenAuthorisedFemale: yes
Male: yes
Phase 2Germany
48NCT00385710November 200619 February 2015Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine)Randomized Placebo-controlled Trial of Valproic Acid in Patients With Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: valproic acid;Drug: PlaceboNantes University HospitalNot recruiting45 Years75 YearsBoth28Phase 2France
49NCT00382824September 200617 August 2015Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP): A Multicenter, Randomized, Placebo-controlled, Double Blind StudyProgressive Supranuclear Palsy;Atypical ParkinsonismDrug: CoenzymeQ10Lahey ClinicNot recruiting30 YearsN/ABoth62Phase 2/Phase 3United States
50EUCTR2005-000574-40-DE24/04/200619 March 2012Brain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon® - N/ABrain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon® - N/APSP is a sporadic neurodegenerative disorder resulting in a Parkinson syndrome with postural instability, oculomotor deficits, and cognitive decline. With an average annual incidence of 5.3 / 100000 and an age-adjusted prevalence of 6.4 / 100000, PSP is as common as motor-neuron disease. The progression of PSP is rapid and the median survival after onset of symptoms is 5-10 years. Presently, there is no known effective symptomatic or neuroprotective therapy for PSP.Product Name: Coenzym Q10 Nanodispersion
Product Code: ASK Nr. 21972
Pharmaceutical Form: Oral drops*
INN or Proposed INN: Ubidecarenon
CAS Number: 303-98-0
Current Sponsor code: Sanomit
Other descriptive name: Coenzym Q10, Ubiquinon, Ubichinon
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: range
Concentration number: 47.5-52.5
Pharmaceutical form of the placebo: Oral drops*
Route of administration of the placebo: Oral use
Kompetenznetz Parkinson e.V.Not RecruitingFemale: yes
Male: yes
30Germany
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
51NCT00139373May 200519 February 2015Study of the Distractibility Syndrome in Patients With Progressive Supranuclear PalsyStudy of the Distractibility Syndrome in Patients With Progressive Supranuclear PalsySupranuclear Palsy, ProgressiveDrug: donepezilGroupe Hospitalier Pitie-SalpetriereInstitut National de la Santé Et de la Recherche Médicale, FranceRecruiting30 Years80 YearsBoth16Phase 2France
52NCT00605930April 200416 December 2017A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy.Energy Metabolism in Neurodegenerative Diseases: A Randomized, Double Blind, Placebo-Controlled Clinical Pilot Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy.Progressive Supranuclear PalsyDietary Supplement: Pyruvate, creatine, niacinamide;Dietary Supplement: PlaceboUniversity of LouisvilleNot recruitingN/AN/AAll20N/AUnited States
53NCT00532571January 200425 June 2018Effects of Coenzyme Q10 in PSP and CBDEffects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot StudyProgressive Supranuclear Palsy;Neurological DisordersDrug: CoQ10Lahey ClinicNot recruiting40 YearsN/AAllPhase 2/Phase 3United States
54NCT00005903June 200019 February 2015Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear PalsyDose-Escalation Trial of Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor for the Treatment of PSPProgressive Supranuclear PalsyDrug: GDNF & Synchro Med Infusion SystemNational Institute of Neurological Disorders and Stroke (NINDS)Not recruitingN/AN/ABoth15Phase 2United States
55NCT00211224April 200019 February 2015Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)Phase 3 Study of Riluzole in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) (Parkinson's Plus Syndromes)Multiple System Atrophy;Progressive Supranuclear PalsyDrug: RiluzoleKing's College LondonAssistance Publique - Hôpitaux de Paris;University of Ulm;Aventis PharmaceuticalsNot recruiting30 Years80 YearsBoth800Phase 3United Kingdom

先頭へ